Intercept Pharma's hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the ...

Researchers for the ongoing 30-year Diabetes Prevention Program found out last week that the NIH canceled funding for the ...

Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis (PBC) patients without cirrhosis, the FDA said in a safety communication ...

Intercept Pharma’s obeticholic acid (OCA) – trying to become the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH) – will come under scrutiny by FDA advisors before the ...

Therapeutic advancements have already begun to show promise. FXR agonists such as obeticholic acid (OCA) have demonstrated potential in reducing liver lipid accumulation and inflammation ...

Therapeutic advancements have already begun to show promise. FXR agonists such as obeticholic acid (OCA) have demonstrated potential in reducing liver lipid accumulation and inflammation ...

Intercept Therapeutics’ efforts with FXR agonist Ocaliva (obeticholic acid) ended in disappointment when the US Food and Drug Administration (FDA) rejected the drug for MASH in 2023, forcing the ...

New treatments, such as obeticholic acid, are being studied and have demonstrated the ability to reduce liver fat and inflammation.” Omega-3s: Consuming fish or Cod Liver Oil capsules regularly ...

Therapeutic advancements have already begun to show promise. FXR agonists such as obeticholic acid (OCA) have demonstrated potential in reducing liver lipid accumulation and inflammation, though ...